Literature DB >> 15965568

Antiarrhythmic action of beta-blockers: potential mechanisms.

Paul Dorian1.   

Abstract

Sympathetic nervous system overactivity has been linked to ventricular tachyarrhythmias and sudden death. It has been hypothesized that the extent and nature of the arrhythmogenic effect of sympathetic stimulation depends on the underlying myocardial substrate, the mechanism of the arrhythmia, and the integrated effects of sympathetic stimulation in the particular individual circumstance. Multiple direct and indirect mechanisms of adrenergic action on the heart may benefit from the known antiarrhythmic actions of beta-blocker therapy and other interventions that decrease sympathetic tone. The antiarrhythmic mechanism of beta-blockade (and possibly alpha-blockade) will depend on the specific mechanism of the individual arrhythmia and will differ for those arrhythmias caused by tachycardia and ischemia, those caused by reentry and promoted by decreased conduction velocity and shortened refractoriness, and those caused by early or delayed afterdepolarizations, usually in the context of prolonged action potential duration. Antagonism of cardiac adrenergic activity by beta-blockade in particular is the best-established drug therapy to prevent ventricular arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15965568     DOI: 10.1177/10742484050100i403

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  12 in total

Review 1.  [Antiarrhythmic therapy with β-receptor antagonists].

Authors:  G C Grönefeld; D Bänsch
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-11-24

Review 2.  2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.

Authors:  Gyorgy Frendl; Alissa C Sodickson; Mina K Chung; Albert L Waldo; Bernard J Gersh; James E Tisdale; Hugh Calkins; Sary Aranki; Tsuyoshi Kaneko; Stephen Cassivi; Sidney C Smith; Dawood Darbar; Jon O Wee; Thomas K Waddell; David Amar; Dale Adler
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-30       Impact factor: 5.209

Review 3.  Neuromodulation for Ventricular Tachycardia and Atrial Fibrillation: A Clinical Scenario-Based Review.

Authors:  Ching Zhu; Peter Hanna; Pradeep S Rajendran; Kalyanam Shivkumar
Journal:  JACC Clin Electrophysiol       Date:  2019-08-19

Review 4.  Cardiac Sympathetic Denervation for the Management of Ventricular Arrhythmias.

Authors:  Stephanie M Kochav; Hasan Garan; Lyall A Gorenstein; Elaine Y Wan; Hirad Yarmohammadi
Journal:  J Interv Card Electrophysiol       Date:  2022-04-09       Impact factor: 1.900

5.  Contributions of ion channel currents to ventricular action potential changes and induction of early afterdepolarizations during acute hypoxia.

Authors:  Namit Gaur; Yoram Rudy; Livia Hool
Journal:  Circ Res       Date:  2009-10-29       Impact factor: 17.367

6.  Facilitation of ischaemia-induced ventricular fibrillation by catecholamines is mediated by β1 and β2 agonism in the rat heart in vitro.

Authors:  Catherine D E Wilder; Nikoleta Pavlaki; Tutku Dursun; Paul Gyimah; Ellice Caldwell-Dunn; Antonella Ranieri; Hannah R Lewis; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

7.  Synthesis of the Ca2+-mobilizing messengers NAADP and cADPR by intracellular CD38 enzyme in the mouse heart: Role in β-adrenoceptor signaling.

Authors:  Wee K Lin; Emma L Bolton; Wilian A Cortopassi; Yanwen Wang; Fiona O'Brien; Matylda Maciejewska; Matthew P Jacobson; Clive Garnham; Margarida Ruas; John Parrington; Ming Lei; Rebecca Sitsapesan; Antony Galione; Derek A Terrar
Journal:  J Biol Chem       Date:  2017-05-24       Impact factor: 5.157

Review 8.  Sympathetic Activation and Arrhythmogenesis after Myocardial Infarction: Where Do We Stand?

Authors:  Konstantinos C Zekios; Eleni-Taxiarchia Mouchtouri; Panagiotis Lekkas; Dimitrios N Nikas; Theofilos M Kolettis
Journal:  J Cardiovasc Dev Dis       Date:  2021-05-15

9.  Cardioprotective and β-adrenoceptor antagonistic activity of a newly synthesized aryloxypropanolamine derivative PP-36.

Authors:  Lokesh K Bhatt; Jyotika Bansal; Poonam Piplani; S L Bodhankar; A Veeranjaneyulu
Journal:  J Exp Pharmacol       Date:  2010-02-11

Review 10.  Atrial Fibrillation: The Science behind Its Defiance.

Authors:  Maureen E Czick; Christine L Shapter; David I Silverman
Journal:  Aging Dis       Date:  2016-10-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.